iNOS (inducible nitric oxide synthase) protein expression is a well-studied predictor of poor outcome in multiple cancers, and it has also been associated with inflammatory and immunosuppressive processes in the tumor microenvironment. Its expression and nitric oxide (NO) production lead to tumor progression by modulation of effector T-cell activity, and its overexpression may allow the tumor to escape the immune response through creating a microenvironment which causes resistance to immunotherapy.
The “10134 – iNOS, Melanoma, TME” APP detects nuclei and classifies them as either negative, 1+, 2+ or 3+ based on the iNOS staining expression present in each nucleus’ vicinity.